RESUMEN
Activation of proliferation of Schwann cells is crucial for axonal guidance and successful nerve regeneration following peripheral nerve injury (PNI). Considering melatonin plays an important role in proliferative regulation of central glial cells, the present study determined whether melatonin can effectively promote Schwann cell proliferation and improve nerve regeneration after PNI. The spontaneous immortalized rat Schwann cell line (RSC 96 cells) was first analyzed by quantitative polymerase chain reaction (QPCR) to detect the potential existence of melatonin receptors. The melatonin receptor-mediated signaling responsible for proliferation was examined by measuring the phosphorylation of extracellular signal-regulated kinases (ERK1/2) pathway. The in vivo model of PNI was performed by the end-to-side neurorrhaphy. The quantity of Schwann cells as well as the number of re-innervated motor end plates (MEP) on target muscles was examined to represent the functional recovery of injured nerves. QPCR results indicated that MT1 is the dominant receptor in Schwann cells. Immunoblotting and proliferation assay revealed an enhanced phosphorylation of ERK1/2 and increased number of RSC 96 cells following melatonin administration. Nonselective melatonin receptor antagonist (luzindole) treatment significantly suppressed all the above findings, suggesting that the proliferative effects of melatonin were mediated by a receptor-dependent pathway. In vivo results corresponded well with in vitro findings in which melatonin effectively increased the amount of proliferated Schwann cells and re-innervated MEP on target muscles following PNI. As melatonin successfully improves nerve regeneration by promoting Schwann cell proliferation, therapeutic use of melatonin may thus serve as a promising strategy to counteract the PNI-induced neuronal disability.
Asunto(s)
Proliferación Celular/efectos de los fármacos , Melatonina/uso terapéutico , Regeneración Nerviosa/efectos de los fármacos , Traumatismos de los Nervios Periféricos/terapia , Células de Schwann/efectos de los fármacos , Animales , Línea Celular , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Masculino , Ratas , Ratas Wistar , Receptor de Melatonina MT1/antagonistas & inhibidores , Transducción de Señal , Triptaminas/farmacologíaRESUMEN
Kinematic approaches using MR images have been regarded of more accuracy in knee pain (AKP) detection than stationary approaches. However, the challenge in segmenting femur, patellar and tibia due to the intensity non-uniformity caused by magnetic propagation degradation in MR images, and the strong adhesion of the soft tissue around the knee organs, has restricted the use of kinematic approaches. This paper proposes a combinatorial based kinematic patellar tracking (CKPT) for AKP detection. The CKPT uses a hybrid approach for extracting knee organs, where an edge-constrained wavelet enhancement followed by moment preserving segmentation is employed for conquering the soft tissue adhesion for extracting the femur and tibia from axial MR images, and a sliding window based moment preserving for resolving the segmentation difficulty associated with intensity non-uniformity in sagittal MR images. The location constraints are then applied for extracting landmark points from femur and patellar, and three inclination angles reflecting patellar position and orientation, during leg movement, are calculated as the measurement of patellar dislocation. The experiment shows that the hybrid approach can accurately extract femur, patellar and tibia. It also demonstrates the prominent of the calculated inclination angles in detecting AKP.
Asunto(s)
Imagen por Resonancia Magnética/estadística & datos numéricos , Dolor/patología , Dolor/fisiopatología , Rótula/patología , Rótula/fisiopatología , Adulto , Fenómenos Biomecánicos/estadística & datos numéricos , Estudios de Casos y Controles , Femenino , Fémur/patología , Fémur/fisiopatología , Humanos , Procesamiento de Imagen Asistido por Computador , Luxación de la Rodilla/diagnóstico , Luxación de la Rodilla/patología , Luxación de la Rodilla/fisiopatología , Masculino , Persona de Mediana Edad , Tibia/patología , Tibia/fisiopatologíaRESUMEN
The potential use of low-dose chemotherapy has been appealing because lower dosages are more attainable during cancer therapy and cause less toxicity in patients. Combination therapy of paclitaxel, a promising frontline chemotherapy agent, with natural anti-tumor agents that are considerably less toxic and possess the capability of activating additional apoptotic signals may provide a rational molecular basis for novel chemotherapeutic strategies. Luteolin, a natural flavone, possesses multiple biological activities, including anti-tumor potential. In the present study, the effects of concomitant administration of luteolin and paclitaxel were investigated in human breast cancer MDA-MB-231 cells. Luteolin alone demonstrated an anti-proliferative effect. Co-administration of luteolin and paclitaxel resulted in an increase in apoptosis compared with the treatment of paclitaxel alone as evidenced by the results of a diamidino-2-phenylindole (DAPI) stain and Annexin-V-based assay. Moreover, immunoblotting analysis also showed that the co-administration of luteolin and paclitaxel activated caspase-8 and caspase-3 and increased the expression of Fas. Furthermore, the increased expression of Fas due to co-administration was shown to be due to the blocking of signal transducer and activator of transcription 3 (STAT3). Finally, combination therapy with luteolin and paclitaxel significantly reduced tumor size and tumor weight in an orthotopic tumor model of MDA-MB-231 cells in nude mice. These results suggest that the luteolin-paclitaxel combination could be a novel strategy for the treatment of breast cancer.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Apoptosis/efectos de los fármacos , Neoplasias de la Mama/tratamiento farmacológico , Luteolina/farmacología , Paclitaxel/farmacología , Factor de Transcripción STAT3/antagonistas & inhibidores , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Femenino , Citometría de Flujo , Humanos , Immunoblotting , Luteolina/uso terapéutico , Ratones , Ratones Desnudos , Paclitaxel/uso terapéuticoRESUMEN
Mechanisms underlying the action of acrylamide on neurons were studied by monitoring the expression of GABA(A) receptor (R) in cultured brain neurons derived from chicken embryos. In situ trypsinization of the neurons and 3H-flunitrazepam binding assay were employed to examine the subcellular distribution of GABA(A)R. A 3-h exposure of the cultured neurons to 10 mM of acrylamide raised reversibly the proportion of intracellular (trypsin-resistant) 3H-flunitrazepam binding sites by about 48% and decreased cell surface binding 24% from respective control values, without altering total cellular binding and the affinity of the ligand. Moreover, the acrylamide treatment induced more intense perikaryal immunostaining of GABA(A)R alpha subunit proteins than that in control neurons but did not change the total level of cellular alpha immunostain, in accordance with the binding data. In the cell bodies of acrylamide-treated neurons, the level of neurofilament-200 kDa proteins was similar to control, whereas the tubulin protein content was significantly lowered approximately 51% from control, as revealed by quantifying the immunostained cytoskeletal elements. In addition, electron microscopic observations found reductions in the numbers of microtubules and neurofilaments in the perikarya of acrylamide-treated neurons. As exhibited by the 3H-leucine and 3H-monosaccharide incorporation experiments, the exposure to acrylamide inhibited the rate of general protein synthesis in the culture by 21%, while the rate of glycosylation remained unaltered. Furthermore, in situ hybridization analysis showed that acrylamide did not modify the expression of GABA(A)R alpha subunit mRNAs. Taken together, these data suggest that acrylamide may downregulate the microtubular system and disintegrate neurofilaments, and thereby block the intracellular transport of GABA(A)R, resulting in the accumulation of intracellular receptors.